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BACKGROUND. In the United States, breast cancer mortality rates are significantly
higher among African-American women than among women of other ethnic back-
grounds. Research efforts to evaluate the socioeconomic, environmental, biologic,
and genetic mechanisms explaining this disparity are needed.
METHODS. Data regarding patterns in the ethnic distribution of physicians and
oncologists were accumulated from a review of the literature and by contacting
cancer-oriented professional societies. This information was evaluated by partic-
ipants in a national meeting, “Summit Meeting Evaluating Research on Breast
Cancer in African American Women.” Results of the data collection and the
conference discussion are summarized.
RESULTS. Ethnic minority specialists are underrepresented in academic medicine
in general, and in the field of oncology in particular. This fact is unfortunate
because ethnic minority students are more likely to express a commitment to
providing care to medically underserved communities and, thus, they need to be
better represented in these professions. Correcting these patterns of underrepre-
sentation may favorably influence the design and implementation of culturally and
ethnically sensitive research.
CONCLUSIONS. Efforts to improve the ethnic diversity of oncology specialists
should begin at the level of recruiting an ethnically diverse premed and medical
student population. These recruitment efforts should place an emphasis on the
value of mentoring. Cancer 2003;97(1 Suppl):329 –34.
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A basic principle of epidemiology and medicine is that disparitiesin disease outcome for different population subsets can be attrib-
uted to variation in disease biology, variation in compliance with
screening and/or disease detection, and variation in access to disease
treatment. This is certainly true for breast cancer in the United States,
where studies have demonstrated consistently a survival disadvan-
329
Published 2003 by the American Cancer Society*
tage for African-American compared with white breast
cancer patients. Aggressive research investigating bi-
ologic variables that may explain this outcome in-
equality is clearly warranted. In addition, and some
might argue more importantly, the oncology commu-
nity must scrutinize every aspect of the health care
delivery system, so that barriers to accessing effective
breast cancer screening, treatment, and risk reduction
programs are dismantled. Strengthening the ethnic
diversity of health care providers, academicians, and
scientists is an essential, but frequently overlooked,
component of efforts to improve the delivery of these
programs to the diverse American public. As popula-
tion demographics continue to evolve, we will be car-
ing for increasing proportions of ethnic minority pa-
tients, and it is critical that the oncology medical
community is prepared to meet the needs of this cul-
turally and ethnically diverse patient population.
Before the Summit Meeting on Breast Cancer
Among African American Women (September 8 –10,
2000, Washington, DC), participants were provided a
draft document of this article. The draft document
cited the importance of increasing the pool of aca-
demically oriented African-American oncologists and
provided demographics that verified the low partici-
pation of African Americans in this profession. After a
plenary session presentation, workshop attendees
evaluated the presentation and provided recommen-
dations. This article represents a summary of the
workshop deliberations and other suggestions that
were made during the course of the workshop and the
summit.
Data from the Association of American Medical
Colleges (AAMC) reveal that underrepresented minor-
ity medical school graduates (defined as medical
school students identifying themselves as African
American, Native American or Native Alaskan, Mexi-
can American, or mainland Puerto Rican) were four
times more likely to seek practices in socioeconomi-
cally deprived areas compared with other medical
school graduates.1 In light of these findings, Dr. Jordan
Cohen outlined the following five compelling reasons
for actively seeking greater diversity within the medi-
cal profession in his presidential address for the 107th
annual AAMC meeting:2
1. Just and equitable access to rewarding careers.
2. Improved access to health care for the underserved.
3. Increasing culturally competent care.
4. Ensuring a comprehensive research agenda
5. Use of the rich and diverse pool of the nation’s
talent to better manage the health care system.
These issues are particularly crucial to the field of
cancer research and treatment because ethnicity-as-
sociated survival disadvantages are significant for
nearly every organ site. Dr. Cohen’s list provides a
convenient framework for a discussion regarding the
importance of encouraging promising young African-
American students to pursue careers in academic
medicine as oncologists and scientists.
Access to Academic Careers
Are sufficient numbers of African-American clinicians
and researchers being trained and seeking careers in
academic oncology? These numbers are difficult to
quantify because many academic professional societ-
ies do not have readily available statistics on the eth-
nic background of their membership. However, we
can glean some clues regarding the extent to which
minorities are underepresented in medical academia
by examining a few areas from which data are col-
lected, including medical school faculty, graduates
from American medical schools, and residents in spe-
cialty training programs.
The American Medical Association3 compiles in-
formation on faculty employed by U.S. medical
schools. According to their 1997 statistics, only 2.6% of
medical school faculty were African American. This
includes 229 of 22,323 (1.0%) African-American pro-
fessors, 418 of 20,300 (2.1%) associate professors, 1195
of 34,373 (3.5%) assistant professors, and 399 of 8841
(4.5%) instructors.
The American College of Surgeons collaborates
with the AAMC in analyzing the ethnic and gender
distribution of trainees in surgical residency pro-
grams. Over the past 10 years, the number of surgeons
completing their residency training has been fairly
consistent at approximately 1000 per year.4 The pro-
portion of ethnic minority residents within this group
has also been consistent, at only 5% per year.
The American Association of Cancer Research re-
viewed their membership data and found some prom-
ising, but disappointing, results. Although the African-
American membership has nearly quadrupled over
the past 8 years, this subset continues to comprise less
than 2% of the total membership for this esteemed
academic oncology society.
There is potential for improving these numbers,
based on the ethnic profile of medical school gradu-
ates. For the 1998 –1999 academic year, African Amer-
icans comprised 1244 of 16,143 (7.7%) medical student
graduates and 1354 of 16,790 (8.1%) first-year medical
students.3 Although these proportions are still under-
representative of the 12% (and rising) African-Ameri-
can population in the United States,5 they do indicate
an expanding pool of talented young physicians who
need to be mentored and recruited for careers in ac-
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ademic oncology. It also is essential that we continue
to fund scholarship programs designed to support the
rising costs of medical education for these students, as
emphasized by Burrow.6
Improved Access to Health Care for the Underserved
The AAMC data regarding the increased likelihood of
ethnic minority medical students to seek careers that
provide service to the socioeconomically disadvan-
taged are strong evidence in support of this assump-
tion. In addition, several studies demonstrate that
there are ethnicity-related variations in the type and
extent of treatment offered to African-American pa-
tients. These ethnicity-related treatment inequalities
occur among patients with cardiac disease7,8 and lung
carcinoma.9 It would be reasonable to assume that
African-American breast cancer patients face similar
barriers. Breen et al.10 found that this was in fact the
case in a review of data from participants in the Na-
tional Cancer Institute’s black-white cancer survival
study. They reported that 21% of black patients failed
to receive “minimum expected therapy” compared
with 15% of white patients (P  0.03).
Presumably, disparities in treatment are related,
at least partially, to suboptimal communication and
educational interaction between health care providers
and African-American patients. Increasing the num-
ber of available African-American clinicians might
ameliorate this problem to some degree. However,
African-American ethnicity does not guarantee empa-
thy and cultural commonality with all medically un-
derserved patients, nor does being white negate the
ability to provide appropriate, culturally sensitive care
to African-American patients. Diversity in the medical
workplace and a commitment to equal employment
opportunities are evidence of a medical institution’s
commitment to providing equality in health care ser-
vices. African-American patients receiving medical
care in institutions that are staffed exclusively by white
physicians may feel estranged from their health care
providers at the start of treatment, and this may jeop-
ardize the likelihood of successful treatment comple-
tion. The sociology and oncology literature suggests
that many African-American patients will have greater
levels of trust in health care institutions staffed by
African-American providers. This importance of the
profile of “the messenger” in delivering health care
information to minority ethnicity communities was
stressed by Nickens,11 Cooper-Patrick et al.,12 Freed-
man,13 and Burrow.6
These problems will be magnified in the face of
socioeconomic disadvantages. Hand et al.14 demon-
strated that breast cancer patients receiving care in
urban hospitals with higher proportions of underin-
sured patients were significantly less likely to have
hormone receptor testing (an essential component of
algorithms defining breast cancer treatment and prog-
nosis) performed on their tumors. They were also less
likely to receive indicated radiation therapy.
The complex relationship between ethnicity, cul-
ture, socioeconomic status, and cancer outcome is
aptly described by Freeman.15 The importance of cul-
turally and ethnically sensitive health awareness ma-
terials targeting medically underserved communities
is stressed in a joint report from the American College
of Surgeons and the American Cancer Society.15 Be-
cause ethnic minority individuals comprise a dispro-
portionately high fraction of medically underserved
communities, it is hoped that input from ethnic mi-
nority health care professionals will improve access to
health care for these patients.
Improving Culturally Competent Care and ensuring a
Comprehensive Research Agenda
Randomized clinical trials are vital components of
cancer research because theyprovide the highest-
quality standards for evidence-based medicine. Re-
sults from clinical trials cannot be generalized to the
entire population unless the participants are truly rep-
resentative of the patient population. As long as eth-
nicity-related disparities in cancer outcome persist,
we are obligated to ensure that new treatment modal-
ities are equally efficacious for diverse patient subsets.
Potential consequences of unsuccessful diversity
in patient accrual were demonstrated in the National
Surgical Adjuvant Breast Project (NSABP) P-1 Study,16
a placebo-controlled trial of tamoxifen for breast can-
cer chemoprevention in high-risk women. Only 1.7%
of the study participants were African American. As a
result, there were no definitive conclusions regarding
the effectiveness of tamoxifen among African-Ameri-
can women. The higher breast cancer mortality rates
seen among African-American women make the po-
tential option of chemoprevention particularly attrac-
tive. However, it is well known that there are age-
related differences in breast cancer incidence between
African-American and white women, with African-
American breast cancer patients having a younger age
distribution.17 In addition, there is ethnicity-related
variation in the incidence of thromboembolic phe-
nomena such as deep vein thrombosis and pulmonary
embolism.18,19 Tamoxifen is associated with an in-
crease in risk for thromboembolic phenomena, but
the increase in risk for this adverse sequela is primarily
seen among women over the age of 50 years.16 The net
result of the overall risks versus benefits of tamoxifen
as chemo preventitive among African-American
women is unknown. Scientific data from the NSABP
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P-1 trial demonstrating a similar activity profile for
tamoxifen in both ethnic groups would have been
ideal. The lack of these data has left patients and
clinicians alike with substantial discomfort regarding a
risk reduction alternative that could potentially save
many lives.
The consequences of clinical trial deficits are
long-standing and extensive. As a result of inadequate
diversity among patients in clinical trials, breast can-
cer risk assessment for African-American women con-
tinues to be poorly understood. The Gail breast cancer
risk assessment model20 is currently the standard for
determining eligibility for chemoprevention consider-
ation in clinical practice and for participation in the
NSABP’s second chemoprevention trial comparing ta-
moxifen and raloxifene. However, the Gail model was
developed from an analysis of breast cancer risk fac-
tors in a case– control study of participants in the
Breast Cancer Detection and Demonstration Project
(BCDDP). The BCDDP was a prospective study of
mammography screening conducted by the American
Cancer Society during the 1970s.21 Only 6% of the
BCDDP participants were African American. There-
fore, this 1989 case– control study of predictive breast
cancer risk factors focused primarily on white pa-
tients, as is demonstrated by the title of the study,
“Projecting individualized probabilities of developing
breast cancer for white females who are being exam-
ined annually.”20 The prevalence of various breast
cancer risk factors varies with ethnic background.22
The extent to which this variation may alter their
causal association with breast cancer is unknown. The
end result is that in the year 2000, we have an effective
means of breast cancer risk reduction for selected
high-risk patients, yet we do not have a validated
model for quantifying breast cancer risk among Afri-
can-American women. This dilemma is related di-
rectly to failures in clinical trial accrual dating back 30
years.
The goal of achieving appropriate diversity in pa-
tient accrual for randomized clinical trials is no longer
merely a concept; it is the law. The NIH Revitalization
Act of 1993, signed into effect by President Clinton,
directs the National Institute of Health to establish
guidelines for inclusion of women and minorities into
clinical trials “in a manner sufficient to provide for
valid analysis of whether the variables being studied in
the trial affect women or members of minority groups,
as the case may be, differently than other subjects in
the trial.” 23
We cannot determine with certainty whether in-
creased recruitment of African-American academi-
cians will solve the problem of improved diversity in
clinical trials enrollment, but it is a reasonable suppo-
sition that the expanded experience and background
of a diverse oncology community will lead to the de-
sign and implementation of culturally and ethnically
sensitive trials. This viewpoint is shared by many re-
spected leaders in the oncology field. The Institute of
Medicine-commissioned committee on cancer re-
search among minorities and the medically under-
served included the following recommendation to the
National Cancer Institute (NCI) in its report on “The
Unequal Burden of Cancer”: “[The] NCI should de-
velop a process to increase the representation of eth-
nically diverse researchers and public representatives
serving on all advisory and program review commit-
tees so that the makeup of these committees reflects
the changing diversity of the U.S. population. [The]
NCI should develop an evaluation plan to assess the
effect of increased and more diversified ethnic minor-
ity community and researcher input on changes in
NCI policies and priorities toward ethnic minority
cancer issues.” 24
In a comprehensive review of strategies aimed at
improving ethnic minority participation in clinical tri-
als, Swanson and Ward25 stressed the importance of
involving ethnic minority health professionals in the
design of the trial and accrual efforts.
Increasing the Quality of Academic Medicine by
Expanding Recruitment Efforts
It is likely that the academic, clinical, and research
arenas are potentially neglecting a large pool of talent
and intellect by not maximizing the recruitment of
ethnic minority clinicians and scientists. In an edito-
rial regarding the importance of these recruitment
efforts, Silen27 commented that it is essential to keep
in mind that the best and the brightest include per-
sons of all races, ethnicities, and genders.
Admittedly, there are some universal barriers to
academic careers that cannot be easily overcome.
Wells27 emphasized the importance of personal drive
and ambition in characterizing academic clinicians,
qualities that are particularly important in an era of
reduced financial compensation for physicians and
scientists. Medical students are graduating with in-
creasing financial indebtedness. These problems may
be magnified for many young ethnic minority physi-
cians who have fewer family and personal economic
resources. Institutions and members of the estab-
lished academic oncology community have an obliga-
tion to address these obstacles. Within the NIH, the
NCI, and the National Institute of Environmental
Health Sciences, grants and funding programs are
available that meet the needs of young researchers
from predominantly ethnic minority medical institu-
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tions. These programs should be publicized widely
and expanded.
Pollock and Curley28 discussed the value of men-
toring young trainees and encouraging them to pursue
fellowship training as a viable route to productive
academic and surgical oncology careers. The impact
of a valuable role model can be generalized to medical
oncology as well as to basic science research. The
commitment to mentor trainees cannot be overem-
phasized in the quest for improving diversity in aca-
demic oncology. This commitment requires time and
outreach efforts. Frequently, mentors are pursued by
aggressive and focused young scientists. However, the
global gain is enhanced if established academicians
actively recruit promising young medical students
and/or residency trainees from their own or from
neighboring programs. The successful mentor will
take the time to guide the aspirations of these talented
trainees toward the extremely rewarding field of aca-
demic oncology research. Assisting the young trainee
in finding suitable academic positions is also impor-
tant and requires a personal willingness to seek the
assistance of colleagues.
The data from this article were discussed at the
summit meeting in Washington, DC. The individuals
who participated in the workshop focusing on this
report drafted the following list of recommendations
aimed at increasing the number of African-American
oncology specialists:
1. Place more emphasis on the important value of
African-American medical and surgical oncologists
by proclaiming their influential roles in a) design-
ing clinical trials that are culturally and ethnically
sensitive and recruiting African Americans into
these trials, b) mentoring future African-American
biomedical researchers, c) serving as role models
for aspiring professionals, d) supporting the plat-
forms of African-American breast cancer advocates,
e) developing policy that addresses the breast care
needs of African-American women, and f) contrib-
uting to the breast care health for all people.
2. Continue to collect data on participation of ethnic
minority groups in cancer-related training pro-
grams and professional societies, expand this data
collection effort, and ensure that gaps in data ac-
quisition do not delay immediate and strong efforts
to enhance recruitment.
3. Increase recruitment efforts at all levels of educa-
tion, including residency, medical school, under-
graduate, and grade school programs.
4. Place more emphasis on early intervention pro-
grams that encourage interest in biomedical fields
through exposure to health care professions during
grade school.29
5. Ensure that grade school teachers and guidance
counselors as well as college faculty and career
counselors are educated and willing participants in
the effort to increase African-American students’
interest in pursuing biomedical professions.
6. Place more emphasis on mentoring programs at all
levels that recruit African American as well as non–
African Americans to serve as mentors. It is through
strong mentoring activities from a multiethnic se-
nior support staff that junior-level individuals will
be afforded a broad spectrum of viable opportuni-
ties for academic and professional growth and suc-
cess.
7. Identify and eradicate the existing barriers (e.g.,
financial, ethnic discrimination, lack of inclusion)
that prevent recruitment, retention, and advance-
ment.
8. Encourage biomedical professional societies to es-
tablish programs designed to encourage participa-
tion of African Americans in society activities. Ex-
amples of such programs might include the
development of minority affairs/special popula-
tions committees, travel awards for minority eth-
nicity students, and mentorship programs.
9. Develop a database of model programs that ad-
dress recruitment of African Americans in biomed-
ical research careers and promote their content as
well as availability through printed materials, vid-
eos, curriculum modules, and the Internet. Ideally,
this database of resources would be maintained by
a well established, national organization.
Ultimately, the worthwhile goal of increasing eth-
nic diversity within the field of academic oncology
requires forethought, sincere commitment, and en-
ergy expenditure on the part of both institutions and
individuals. In the interest of our enlarging ethnic
minority cancer patient population, we cannot afford
to neglect this responsibility.
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